000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c16649 _d16649 |
||
003 | PC16649 | ||
005 | 20230610062758.0 | ||
008 | 211108b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_91082 _aCiruelos Gil, Eva María _eOncología Médica |
||
100 |
_92957 _aPascual Martínez, Pascual _eOncología Médica |
||
100 |
_92958 _aArroyo Vozmediano, María Luisa _eObstetricia y Ginecología |
||
100 |
_92959 _aBlanco Guerrero, Marta _eObstetricia y Ginecología |
||
100 |
_9432 _aManso Sánchez, Luis _eOncología Médica |
||
100 |
_92960 _aParrilla Rubio, Lucía _eOncología Médica |
||
100 |
_92961 _aMuñoz, César _eOncología Médica |
||
100 |
_9301 _aVega Alonso, Estela _eOncología Médica |
||
100 |
_92962 _aCalderón, Monica Jackelin _eOncología Médica |
||
100 |
_92963 _aSancho, Blanca _eObstetricia y Ginecología |
||
100 |
_91181 _aCortés-Funes Castro, Hernán _eOncología Médica |
||
245 | 0 | 4 |
_aThe therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. _h[revisión] |
260 |
_bThe Breast : official journal of the European Society of Mastology, _c2014 |
||
300 | _a23(3):201-8. | ||
500 | _aFormato Vancouver: Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014 Jun;23(3):201-8. | ||
501 | _aPMID: 24589524 | ||
504 | _aContiene 51 referencias | ||
520 | _aAlthough selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant. Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy. The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs. Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile. In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed. | ||
710 |
_9303 _aServicio de Oncología Médica |
||
710 |
_9427 _aServicio de Obstetricia y Ginecología |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16649.pdf _ySolicitar documento |
||
942 |
_2ddc _cREV _n0 |